… American Academy of Optometry (AAOpt) Annual Meeting 2020 American Academy of … 2020 ProQR to participate in the American Academy of Optometry (AAOpt) Annual Meeting 2020 . Qua, 07/10/2020 - …
… sepofarsen captain. The work of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 … in Venezuela and now heading ProQR’s LCA research and development team in Leiden (The Netherlands), has multiple reasons for being optimistic. Obviously, as a biotech scientist looking for a …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of … RNA therapies.” But what about gene therapy, isn’t that an option? “There are several reasons to choose RNA therapy over … Can we learn more about our molecules, and does it help to optimize our protocols? Those are just some of the questions …
… with Lilly and Company . The partnership focuses on developing potential medicines using our Axiomer ® RNA … is to progress new medicine technology towards clinical development and, ultimately, to patients via … into diseases of which there are little to no treatment options. In our vision partnerships are true catalyst for the …
… collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing … beginning, ProQR has been focused on RNA technologies to develop medicines for people and families with high unmet … additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and …
… Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of designing medicines for genetic … variety of diseases with currently no or limited treatment options. A new approach The Axiomer® technology builds on …
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
… in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, … on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and … Principal Researcher at ProQR "I work on designing and optimizing new therapies" Nanyamka Braham from Regulatory …
